The value: why localisation pays off across global trials
June 26, 2026 | Localisation, clinical trials, translation
Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.
In our first two articles, we looked at where translation falls short and what good localisation actually looks like. Now we come to the part that affects timelines, budgets and trial delivery: the operational impact of getting localisation wrong.
Poor localisation rarely announces itself. It shows up quietly, in extra questions, slower processes, and avoidable rework. Strong localisation does the opposite. It keeps trials moving and helps sites focus on participants.
Where poor localisation creates friction
When materials don’t quite land, the effects ripple across sites and regions. Teams often see more site queries, with participants asking staff to explain content that should already be clear. Consent and onboarding slow down as confusion delays decisions. And when materials need revising market by market after launch, rework quickly builds.
These aren’t isolated problems. In our recent report The Site Factor, 27% of European respondents cited delays in receiving sponsor materials as their biggest barrier to enrolling participants. Just 24% of site teams say they use sponsor-provided materials, while others supplement them with their own materials or report having no participant-facing materials at all.
The hidden cost of fixing content late
Fixing localisation late is far more expensive than getting it right early. A single change to a master document can trigger updates across every language version, requiring fresh review, approval and redistribution. When amendments arrive out of sequence, sites are left unsure what to apply and when.
That uncertainty has a cost. It pulls site staff away from participants, adds review cycles, and risks inconsistency across regions. The later you spot the gap, the wider it spreads.
How strong localisation supports smoother delivery
Done well, localisation removes friction before it starts. Content arrives ready to use, reducing the burden on site teams to interpret, adapt or explain materials that participants find difficult to understand.
Across a trial, those benefits add up: fewer clarification queries for site staff, more consistent understanding across markets, smoother consent and onboarding processes, and less need for local workarounds or supplementary materials.
When participants understand what’s being asked of them, they’re more likely to engage and stay. And a better participant experience links directly to greater study completion.
Localisation, risk and diversity
Localisation isn’t just about clarity. It’s about reach. If your materials only work for some communities, your trial only reaches those communities. That limits diversity and skews representation, ultimately affecting the quality of the data generated.
Strong localisation helps you recruit fairly across regions and cultures. It reduces protocol misunderstandings, supports adherence, and lowers the risk of avoidable delays. In short, it makes trials more efficient and more representative.
Bringing the series together
Across these three articles, one idea has stayed constant. While translation carries the language, localisation carries the meaning.
That difference shapes how participants interpret, trust and engage with your trial. Treat localisation as a core part of your trial communication strategy, not a final production step, and you’ll see the value in smoother delivery, stronger engagement and better outcomes for everyone involved.
And that’s a goal worth building towards.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Where translation falls short in practice
Discover why translation alone is not enough in global clinical trials and how expert localisation improves participant understanding, trust and engagement.
Where it all began – why we developed The Experience Gap
Learn how The Experience Gap was developed to help sponsors, CROs and site teams improve clinical trial participation by identifying friction points, enhancing patient experience, and driving better recruitment and…
Cuttsy+Cuttsy launches a practical roadmap to enhance clinical trial participant experience
Cuttsy+Cuttsy has launched The Experience Gap, a practical roadmap designed to help clinical trial teams improve participant engagement, support and retention across the full study journey.
Cuttsy+Cuttsy welcomes three new experts to the team
Cuttsy+Cuttsy is happy to be welcoming three new people to the team this month.
The gap between hype and reality, what patients really say about weight loss drugs
Explore real patient conversations about weight loss drugs, uncovering challenges, support strategies, and the critical need for clear, reliable healthcare communication.
Why patient-centricity depends on site-centricity in clinical trials
Explore why patient-centricity in clinical trials relies on site-centricity, emphasising the need to design trials that empower site teams to better support patients.
From cloudy to clear: visualising complex data privacy information
Discover how clear communication principles can transform complex clinical research topics, as we conclude our Health Literacy series with a practical example on participant data transparency.
UK clinical trial regs are changing — here’s what’s happening
Discover the transformative updates to UK clinical trial regulations, effective from April 2026, and learn how they aim to enhance transparency, participant safety, and trial efficiency.
The invisible influence on trial retention: why caregivers must be part of the plan
Caregivers are vital to clinical trial retention, yet often overlooked—this article highlights their challenges, impact, and how to better support them.
Where it all began: why we wrote ‘The Site Factor’
Discover the story behind ‘The Site Factor’ and how understanding site teams’ experiences can transform clinical trials for participants and researchers alike.